This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.
TruSight Oncology 500 DNA Kit for Use with NextSeq plus Pierian interpretation report (16 indexes, 48 Samples)
20032625
TruSight Oncology 500 DNA/RNA Bundle plus Pierian interpretation report (16 indexes, 24 Samples)
20032626
TruSight Oncology 500 DNA/RNA Kit for Use with NextSeq plus Pierian interpretation report (16 indexes, 24 Samples)
20032627
TruSight Oncology 500 DNA Automation Kit plus Pierian interpretation report (16 indexes, 64 samples)
20045506
TruSight Oncology 500 DNA Automation Kit plus Pierian interpretation report, for Use with NextSeq (16 indexes, 64 samples)
20045507
TruSight Oncology 500 DNA/RNA Automation Kit plus Pierian interpretation report (16 indexes, 32 Samples)
20045509
TruSight Oncology 500 DNA/RNA Automation Kit, For Use with NextSeq (16 indexes, 32 Samples)
20045990
TruSight Oncology 500 DNA/RNA Automation Kit plus Pierian interpretation report, For Use with NextSeq (16 indexes, 32 Samples)
20045991
ICA Basic Annual Subscription
20044874
ICA Professional Annual Subscription
20044876
ICA Enterprise Annual Subscription
20038994
ICA Enterprise Service and Compliance Add-on (applies to Basic only)
20066830
Illumina Connected Insights-Annual Subscription
20090137
Illumina Connected Insights‒Oncology Genome Equivalent Sample-VCF
20090138
Illumina Connected Insights‒Training and Onboarding
20092376
Informatics Professional Services
20071787
TruSight Oncology 500 is a next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples. It supports identification of all relevant DNA and RNA variants implicated in various solid tumor types.
In addition, it accurately measures key current immuno-oncology biomarkers: microsatellite instability (MSI) and tumor mutational burden (TMB).
TruSight Oncology 500 HRD* is an optional add-on kit to TruSight Oncology 500 and enables detection of homologous recombination deficiency (HRD) through assessment of a genomic instability score (GIS). This represents an exciting new advancement to the TruSight Oncology portfolio.
*Not available in Japan.
Consolidate Multiple Biomarker Assays into One
Streamlined Sample-to-Results Workflow
† Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
Achieve Highly Confident Results
Enable In-House Comprehensive Genomic Profiling
Fast, Automation-friendly Workflow
Prepare libraries for Illumina sequencing in less than a day. Illumina Qualified Methods are available on a range of automation platforms through our partners.
Learn more about the TruSight Oncology Product FamilyAll three TruSight Oncology 500 assays are designed to identify key biomarkers in guidelines and clinical trials.
Assess relevant biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.
Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.
Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.
Complete the form to receive information about the first-time TruSight Oncology 500 purchase program.
TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | TruSight Oncology 500 ctDNA | |
---|---|---|---|
Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer |
Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1* • TruSight Oncology 500 HRD** kit content includes coverage of ~25,000 SNP's to assess homologous recombination deficiency through a comprehensive genomic instability score (LOH+TAI+LST), powered by Myriad Genetics • TruSight Oncology 500 HRD** is an optional add-on kit to TruSight Oncology 500 **Not available in Japan |
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. • Immuno-oncology Biomarker Coverage: TMB and MSI • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 600 clinical trials* |
Targeted selection of 523 genes (full coding sequence) for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Immuno-oncology Biomarker Coverage: TMB and MSI* |
Hands-On Time | Manual: ~10.5 hrs Automated: ~2.5 hrs (TruSight Oncology 500 only) |
Manual: ~10.5 hrs Automated: ~2.5 hrs |
Manual: ~10.5 hrs Automated: N/A |
Input Quantity | 40 ng DNA, 40 ng RNA | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 30 ng cfDNA (8-10 ml of plasma) |
Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing |
Nucleic Acid Type | RNA, DNA | RNA, DNA | DNA |
Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Circulating Tumor DNA |
Species Category | Human | Human | Human |
System Compatibility | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000, NovaSeq 6000Dx in Research Mode | NovaSeq 6000 |
Technology | Sequencing | Sequencing | Sequencing |
Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Somatic Variants |
* Based on Pierian clinical knowledgebase, as of February 2023.
† NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
The TruSight Oncology 500 Analytical Evaluation Service* is a set of tools intended to guide you in aligning with the latest CAP, AMP, and European standards. We provide recommendations to help you evaluate analytical performance characteristics and integrate products into your workflows.
Learn More* This service is available in select countries and regions.
Pan-cancer: BRAF, NTRK1, NTRK2, NTRK3, RET, MSI, TMB | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Genes with biomarkers of significance* | Genes with biomarkers of potential significance† | ||||||||||
Breast |
BRCA1 | BRCA2 | ERBB2 | ESR1 | PALB2 | PIK3CA | 180 | ||||
Colorectal |
ERBB2 | KRAS | NRAS | 166 | |||||||
Bone |
EGFR | ERG | ETV1 | ETV4 | EWSR1 | FEV | FLI1 | FUS | H3F3A | HEY1 | 140 |
IDH1 | MDM2 | NCOA2 | SMARCB1 | ||||||||
Lung |
ALK | EGFR | ERBB2 | KRAS | MET | NUTM1 | ROS1 | 223 | |||
Melanoma |
KIT | NRAS | ROS1 | 172 | |||||||
Ovarian |
BRCA1 | BRCA2 | FOXL2 | 149 | |||||||
CNS |
APC | ATRX | CDKN2A | CDKN2B | EGFR | H3F3A | HIST1H3B | HIST1H3C | IDH1 | IDH2 | 140 |
MYCN | PTCH1 | RELA | TERT | TP53 | |||||||
Prostate |
AR | ATM | BARD1 | BRCA1 | BRCA2 | BRIP1 | CDK12 | CHEK1 | CHEK2 | FANCL | 151 |
FGFR2 | FGFR3 | PALB2 | RAD51B | RAD51C | RAD51D | RAD54L | |||||
Thyroid |
HRAS | KRAS | NRAS | RET | TERT | 165 | |||||
Uterine & cervical |
BRCA2 | EPC1 | ERBB2 | ESR1 | FOXO1 | GREB1 | JAZF1 | NCOA2 | NCOA3 | NUTM2A | 138 |
NUTM2B | PAX3 | PAX7 | PHF1 | POLE | SMARCA4 | SUZ12 | TP53 | YWHAE | |||
Other Solid Tumors |
ALK | APC | ARID1A | ASPSCR1 | ATF1 | ATIC | BAP1 | BCOR | BRCA1 | BRCA2 | 152 |
CAMTA1 | CARS | CCNB2 | CDK4 | CDKN2A | CIC | CITED2 | CLTC | COL1A1 | COL6A3 | ||
CREB1 | CREB3L1 | CREB3L2 | CSF1 | CTNNB1 | DDIT3 | DDX3X | DNAJB1 | DUX4 | EED | ||
EGFR | ERBB2 | ERG | ETV1 | ETV4 | ETV6 | EWSR1 | FEV | FGFR2 | FGFR3 | ||
FLI1 | FOXL2 | FOXO1 | FOXO4 | FUS | GLI1 | HEY1 | HGF | HMGA2 | IDH1 | ||
KRAS | LEUTX | MAML3 | MDM2 | MYB | MYOD1 | NAB2 | NCOA2 | NF1 | NFATC2 | ||
NFIB | NR4A3 | NRAS | NUTMI | NUTM2A | NUTM2B | PALB2 | PATZ1 | PAX3 | PAX7 | ||
PDGFB | PDGFRA | PRKACA | PRKD1 | RANBP2 | ROS1 | SDHA | SDHB | SDHC | SDHD | ||
SMARCB1 | SS18 | SSX1 | SSX2 | SSX4 | STAT6 | SUZ12 | TAF15 | TCF12 | TERT | ||
TFE3 | TFEB | TFG | TP53 | TPM3 | TPM4 | TRAF7 | TSPAN31 | VGLL2 | WT1 | ||
WWTR1 | YAP1 | YWHAE | ZC3H7B |
The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on this page.
* The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Analysis of TMB and MSI Status with TruSight Oncology 500
Application Note | HTML
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF < 1 MB
Input Recommendations for TMB, MSI, and Small Variant Analysis with TruSight Oncology 500
Technical Note | HTML
TruSight Oncology 500 Gene List
product_file | EXCEL < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Data Sheet | PDF | 7 versions
Data Sheet | PDF | 6 versions
DRAGEN TruSight Oncology 500 Analysis Software v1.1 Documentation
TruSight Oncology 500 v1.0 Local App Documentation
TruSight Oncology 500 v2.0 Local App Documentation
TruSight Oncology 500 v2.1 Local App Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1 Documentation
DRAGEN TruSight Oncology 500 Analysis Software v1.1 on ICA Documentation
DRAGEN TruSight Oncology 500 Analysis Software v2.1.1 on ICA Documentation
TruSight Oncology 500 Support Documentation